Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis

Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis (REACT-CF)

This is a pilot study investigating the effectiveness and clinical efficacy of airway clearance therapy (ACT) in cystic fibrosis (CF). Enrolled subjects will undergo measurements of mucociliary clearance (MCC) and exhaled biomarkers at baseline and after 3 different forms of ACT: high frequency chest wall oscillatory vest, oscillatory positive expiratory pressure device, and whole-body vibration.

Inclusion Criteria:

• Adults with confirmed diagnosis of cystic fibrosis aged 18 years and older.

Exclusion Criteria:

• Pregnant or lactating women,
• Individuals with severe lung disease (FEV1 <30%), or with exacerbations of lung disease requiring antibiotics or medication change within four weeks prior to enrolment.
• Individuals unable to use vest-based HFCWO, OPEP device, or who require oxygen supplementation at rest.
• Individuals with significant balance or gait impairment preventing them from tolerating being positioned on a vibrating platform.